CAR-T Cells Targeting IL-1RAP for CML Stem Cell Elimination
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for chronic myelogenous leukemia (CML), particularly tyrosine kinase inhibitors (TKIs), fail to eradicate quiescent CML stem cells, leading to relapse and requiring continuous long-term administration with potential adverse events, and do not address the persistence of disease reservoirs.
Innovation Solution
Development of genetically modified CAR-T cells expressing an anti-IL-1RAP binding domain to target and eliminate CML stem cells, offering a curative approach by redirecting cytotoxicity towards tumor cells independently of HLA restriction.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If tyrosine kinase inhibitors (TKIs) are used to treat CML, then survival is improved and disease control is achieved, but quiescent CML stem cells persist leading to relapse and requiring continuous long-term administration
Solution Approach 1:
The patent replaces the pharmacological mechanism of TKIs with a biological immunological mechanism. CAR-T cells use their chimeric antigen receptors to directly recognize and eliminate IL-1RAP-expressing CML stem cells through cytotoxic T cell activity, replacing the need for continuous drug administration with a self-sustaining immune response that can eradicate persistent disease reservoirs.
Solution Approach 2:
The CAR-T cells are designed to be autonomous effectors that can independently recognize, bind to, and eliminate target cells through their chimeric antigen receptors. Once infused, they self-activate and sustain their cytotoxic function without requiring external pharmacological intervention, enabling long-term disease control through the patient's own immune system.
2Reliability
If allogeneic stem cell transplantation is used to treat CML, then curative potential is improved, but transplant-related mortality and relapse risks increase
Solution Approach 1:
The patent extracts the curative potential from the high-risk allogeneic transplant approach by using autologous CAR-T cell therapy. Instead of requiring donor matching and complex transplantation procedures, the therapy extracts and amplifies the patient's own T cells, genetically modifies them to express CARs specific for IL-1RAP, and reinfuses them to eliminate CML stem cells, thereby achieving curative intent without the associated mortalities and relapse risks of allogeneic transplantation.
Solution Approach 2:
The patent changes the fundamental parameter of the therapeutic approach from cellular transplantation (allogeneic stem cells) to cellular immunotherapy (CAR-T cells). This parameter change transforms the mechanism of action from engraftment and graft-versus-leukemia to targeted cytotoxicity against specific antigen-expressing cells, eliminating the need for donor matching and reducing transplant-related complications while maintaining curative potential.
3Reliability
If TKI therapy is administered continuously, then disease suppression is improved, but adverse events and toxicities increase
Solution Approach 1:
The patent substitutes the pharmacological suppression mechanism of TKIs with a biological elimination mechanism. CAR-T cells directly target and destroy IL-1RAP-expressing CML stem cells through cytotoxic T cell activity, replacing the indirect pharmacological suppression with direct cellular eradication. This substitution eliminates the need for continuous drug administration and its associated adverse events and toxicities.
Solution Approach 2:
The patent converts the persistence of quiescent CML stem cells, which previously represented a harmful resistance mechanism requiring continuous TKI therapy, into a beneficial target for CAR-T cell therapy. By designing CARs that specifically recognize IL-1RAP on these persistent stem cells, the therapy transforms the previously harmful persistence into a vulnerable target for selective elimination, thereby achieving disease control without continuous drug administration and its associated toxicities.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The CAR-T cells effectively target and eliminate IL-1RAP-expressing CML cells, potentially providing a durable solution to CML, reducing the need for continuous TKI therapy and minimizing toxicities, and are effective in relapsed or resistant cases, including young patients.
Implementation Method 1
redirecting cytotoxicity towards tumor cells
Data Source
AI summary
The present invention is relative to an isolated nucleic acid molecule encoding a chimeric antigen receptor (CAR), wherein the CAR comprises an antibody or antibody fragment which includes a anti-IL-1RAP binding domain, polypeptides encoded by this nucleic acid molecule, isolated chimeric antigen receptor (CAR) molecule comprising such an antibody or antibody fragment, a vector comprising a nucleic acid molecule encoding a CAR, as well as a T cell comprising this vector. The present invention is also relative to the use of this T cell (autologous or allogeneic) expressing a CAR molecule to treat a proliferative disease in a mammal.